Trial Profile

A Phase 2a, randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of PTC518 in subjects with Huntington's disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Votoplam (Primary)
Indications Huntington's disease
Focus Adverse reactions; Therapeutic Use
Acronyms PIVOT-HD
Sponsors PTC Therapeutics

Most Recent Events

21 Jul 2026 Interim Results presented in the Novartis media release.
28 Apr 2026 Interim Results presented in the PTC Therapeutics Media Release
28 Apr 2026 According to a PTC Therapeutics media release, company will host a webcast conference call on April 28 at 4:30 p.m. ET to share results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com